Replies to post #111476 on NanoViricides Inc. (NNVC)

[Snowy_Owl]

Substantiate or retract.

"...the failure of Ebolacide 1 and 2. The cide platform obviously doesn't work!!!!

[winstreak]

Please define "Doesn't work"!

So Ebolacide I and Ebolacide II both showed zero effectiveness against Ebola?

Also please update us on the failure of Ebolacide 1 and 2. The cide platform obviously doesn't work!!!!

[NewMoney]

You mean it's not plug and play and cures any virus? ROFL

[changes_iv]

Your post is "incomplete, incorrect," and lacking in context." I don't see proof of your claims. My first question: how many candidates did NanoViricides, Inc. ship to USAMRIID? Did they ship 18, 24, etc.? This is the most recent news PR we got from NanoViricides, Inc. on Ebola:

Ebola
Using NanoViricides's rapid design platform, it took only 4 months from design to synthesis of the multiple EbolaCide drug candidates needed for study. In late January, these novel anti-Ebola drug candidates were sent to our collaborating BSL-4 facility for initial testing. Our drug candidates were found to be broad-spectrum, in that they were equally effective against Ebola virus as well as Marburg viruses. This is unlike the antibody-based, siRNA-based and antisense-based anti-Ebola therapeutics currently being advanced, which only work against specific strains with a very narrow and selective spectrum of activity. Broad-spectrum activity of our drug candidates is a very important and valuable characteristic, as it indicates that mutations of the virus in the field are unlikely to cause escape of the virus from our final EbolaCide™ drug. We believe that with the new insight we have gained, and with our experience from earlier studies, we can continue to optimize our multiple drug candidates before another Ebola epidemic strikes. The recent outbreak in Africa, though now waning, has unequivocally demonstrated the need for an effective, broad-spectrum, anti-Ebola therapeutic in order to control any further outbreaks.
http://www.nanoviricides.com/press%20releases/2015/NanoViricides%20Provides%20an%20Update%20on%20Its%20Progress%20over%20the%20Last%20Quarter.html

Before we get to a final Ebola candidate (singular) we will be reading about Ebola candidates (plural) as we did for FluciDe(TM).

NanoViricides Reports FluCide™ Drug Candidates Found to Offer Significant Reduction in Damaging White Blood Cell Presence
http://www.nanoviricides.com/press%20releases/2011/NanoViricides%20Reports%20FluCide%20Drug%20Candidates.html

Both the oral and the injectable FluCide drug candidates have shown extremely high effectiveness in highly lethal mouse models of two distinctly different influenza A virus infections, viz. H1N1 and H3N2, indicating that FluCide drugs indeed have a broad-spectrum effect against influenza viruses, irrespective of the subtype or strain.

In these highly lethal studies, FluCide drug candidates have achieved complete survival (22+ days), while in contrast, Tamiflu® (oseltamivir) resulted in only 8-9 days survival, and the untreated animals die within 5 days. The FluCide oral and injectable drug candidates also protected the lungs of the animals much better than did oseltamivir, indicating a clear benefit. The protection from influenza virus was clearly reflected in the strong increase in survival time in the FluCide-treated animals as compared to oseltamivir. The FluCide drugs were seen to be far superior to Tamiflu also in terms of viral load reduction. The FluCide drugs were extremely well tolerated, in contrast to oseltamivir. No dose-limiting side effects have been seen for our FluCide candidates as yet, indicating that in a severely ill patient, the dosage of FluCide can be increased even further. In these animal studies, the mouse serves only as a “test tube” and FluCide is designed to attack the virus (not the host). Thus the results are expected to correlate well with the impending human clinical studies.
http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Anticipates%20FluCide%E2%84%A2%20Drug%20Candidates%20to%20be%20Effective%20Against%20H7N9.html

Where do you get it was a dud? Try to be more credible and cite your sources!
=======================================

Ebola Virus: Film reveals scenes of horror in Liberia - BBC News

Ebola outbreak: Virus mutating, scientists warn
By Tulip Mazumdar Global health reporter
29 January 2015



"We know the virus is changing quite a lot," said human geneticist Dr Anavaj Sakuntabhai.

A virus can change itself to less deadly, but more contagious and that's something we are afraid of
Dr Anavaj Sakuntabhai, Geneticist

"That's important for diagnosing (new cases) and for treatment. We need to know how the virus (is changing) to keep up with our enemy."

It's not unusual for viruses to change over a period time. Ebola is an RNA virus - like HIV and influenza - which have a high rate of mutation. That makes the virus more able to adapt and raises the potential for it to become more contagious.

"We've now seen several cases that don't have any symptoms at all, asymptomatic cases," said Anavaj Sakuntabhai.

"These people may be the people who can spread the virus better, but we still don't know that yet. A virus can change itself to less deadly, but more contagious and that's something we are afraid of."
Latest figures

There were fewer than 100 new cases in a week for the first time since June 2014.

In the week to 25 January there were 30 cases in Guinea, four in Liberia and 65 in Sierra Leone.

The World Health Organization says the epidemic has entered a "second phase" with the focus shifting to ending the epidemic.

But Prof Jonathan Ball, a virologist at the University of Nottingham, says it's still unclear whether more people are actually not showing symptoms in this outbreak compared with previous ones.

"We know asymptomatic infections occur… but whether we are seeing more of it in the current outbreak is difficult to ascertain," he said.

"It could simply be a numbers game, that the more infection there is out in the wider population, then obviously the more asymptomatic infections we are going to see."
The current outbreak began in south-eastern Guinea and spread to Liberia and Sierra Leone

Another common concern is that while the virus has more time and more "hosts" to develop in, Ebola could mutate and eventually become airborne.

There is no evidence to suggest that is happening. The virus is still only passed through direct contact with infected people's body fluids.

"No blood borne virus, for example HIV or Hepatitis B, has ever shown any indication of becoming airborne. The mutation would need to be major," said infectious disease expert Professor David Heyman.

Virologist Noel Tordo from the Institut Pasteur is in the Guinea capital Conakry. He said:

"At the moment, not enough has been done in terms of the evolution of the virus both geographically and in the human body, so we have to learn more. But something has shown that there are mutations.

"For the moment the way of transmission is still the same. You just have to avoid contact (with a sick person).

"But as a scientist you can't predict it won't change. Maybe it will."

Researchers are using a method called genetic sequencing to track changes in the genetic make-up of the virus. So far they have analysed around 20 blood samples from Guinea. Another 600 samples are being sent to the labs in the coming months.

A previous similar study in Sierra Leone showed the Ebola virus mutated considerably in the first 24 days of the outbreak, according to the World Health Organization.

It said: "This certainly does raise a lot of scientific questions about transmissibility, response to vaccines and drugs, use of convalescent plasma.

"However, many gene mutations may not have any impact on how the virus responds to drugs or behaves in human populations."

'Global problem'

The research in Paris will also help give scientists a clearer insight into why some people survive Ebola, and others don't. The survival rate of the current outbreak is around 40%.

It's hoped this will help scientists developing vaccines to protect people against the virus.

Researchers at the Institut Pasteur are currently developing two vaccines which they hope will be in human trials by the end of the year.

One is a modification of the widely used measles vaccine, where people are given a weakened and harmless form of the virus which in turn triggers an immune response. That response fights and defeats the disease if someone comes into contact with it.

The research may explain why some people survive Ebola and others do not

The idea, if it proves successful, would be that the vaccine would protect against both measles and Ebola.

"We've seen now this is a threat that can be quite large and can extend on a global scale," said Professor James Di Santo, and immunologist at the Institut.

"We've learned this virus is not a problem of Africa, it's a problem for everyone."

He added: "This particular outbreak may wane and go away, but we're going to have another infectious outbreak at some point, because the places where the virus hides in nature, for example in small animals, is still a threat for humans in the future.

"The best type of response we can think of… is to have vaccination of global populations."
http://www.bbc.com/news/health-31019097

2 New Ebola Vaccines Pass Important Early Test, Researchers Say
...
The two newer vaccines are being made by Profectus BioSciences. The company’s chief scientific officer, John Eldridge, said the company had received $55 million in recent months to work on Ebola vaccines from a consortium of government agencies that includes the National Institutes of Health and the Department of Defense. He said that Profectus was also working on another vaccine that would protect people against several strains of Ebola as well as Marburg, a related virus. None of the vaccines is likely to be approved much before 2017, he said.
http://www.nytimes.com/2015/04/09/health/2-new-ebola-vaccines-pass-important-early-test-researchers-say.html?_r=0